Brind.
  1. Avadel Pharmaceuticals sought FDA approval for new indications and secured an exclusive licensing deal with XWPharma.

Avadel Pharmaceuticals secured an exclusive global license agreement with XWPharma for the development of valiloxybate.

1 report, 1 independent Updated Sep 4
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Avadel Pharmaceuticals secured an exclusive global license agreement with XWPharma for the development of valiloxybate.

Who's involved

What this event is mainly about
Avadel PharmaceuticalsXWPHARMA

Keep exploring

Part of

Avadel Pharmaceuticals sought FDA approval for new indications and secured an exclusive licensing deal with XWPharma. All 1 developments

The entities involved

Coverage

Newest first; wire copies grouped
  • GlobeNewswireAvadel Pharmaceuticals Strengthens Sleep Medicine Portfolio with Exclusive License of Valiloxybate from XWPharma Ltd – Expands Avadel’s pipeline with salt-free, artificial sweetener-free, once-at-bed